UK Patent Application GB 2 136 314 A

(43) Application published 19 Sep 1984

(21) Application No 8406437

(22) Date of filing 12 Mar 1984

(30) Priority data

(31) 475047

(32) 14 Mar 1983

(33) US

(71) Applicant Gelman Sciences Inc, (USA-Michigan), 600, South Wagner Rd, Ann Arbor, Michigan 48108, United States of America

(72) Inventors

Monty E. Vincent,

Attila Vadnay

(74) Agent and/or address for service Urquhert-Dykes & Lord, 47, Marylebone Lane, London, W1M 6DL

(51) INT CL3 A61M 1/03 B01D 13/00 // G01N 1/20

(52) Domestic classification B1X 6A1 6B3 6F4 6F6 6J3 B1D 1510 1806 1819 1821 1902 2301 KC G1B CE U1S 1030 1047 1052 1296 2159 B1D B1X

(56) Documents cited

GB A 2086761 GB

1312498

1283273=US 3705100

EΡ 0070738

3905905 US

(58) Field of search


B₁X


GB


B1D

(54) Filter and Method for Obtaining Blood Plasma Samples

(57) The filter is for use during hemodialysis and is of the cross-flow type having a blood flow chamber 45 through which the blood flows and a plasma chamber 46 separated from the blood flow chamber by a filter medium 32 which enables the passage of the plasma therethrough while blocking the passage of the red cells of the blood, the plasma chamber having a volume not exceeding about 2 milliliters. In the preferred use the plasma chamber is filled with saline solution except when a plasma sample is taken at which time the saline solution is first withdrawn and then the plasma sample is withdrawn through a sealable opening 38, after which the plasma chamber is again filled with saline solution whereupon plasma in the plasma chamber flows back through the filter medium into the blood flowing through the flow chamber. The filter and method enable accurate periodic analysis of the patient's blood plasma without any loss of red cells to the patient and with minimal loss of plasma.







SPECIFICATION Filter and Method for Obtaining Blood Plasma Samples

Technical Field

The subject matter of the present invention is a filter and method for obtaining blood plasma samples from a patient, particularly while under nemodialysis treatment.

Background Art

It is well known that patients with defective or diseased kidneys require periodic hemodialysis to remove from the blood, i.e. from the plasma component of the blood, the accumulation of generated waste products which in healthy

persons are continuously removed by the kidneys. The dialyzer systems used are commonly referred to as artificial kidneys. Such hemodialysis is effective in removing waste products from the blood stream by a cleansing action at the

hemodialysis membrane. As the patient's blood is pumped continuously through the artificial kidney in a generally four to six hour treatment, a dialyzate, i.e. a cleansing fluid containing necessary salt solutions, is pumped along the

25 other side of the membrane. By diffusion, the chemicals that accumulate daily due to kidney failure are transferred from the blood through the membrane and are washed away by the dialyzate. Fluid that accumulates in the blood in the absence 30 of urine output is also removed across this

membrane by generation of a hydrostatic pressure from the blood to the dialyzate. This treatment is usually required three times weekly and is highly effective.

Full rehabilitation of patients with kidney 35 failure is, however, limited by a severe anemia that is very common in these patients. This anemia is mainly due to the lack of erythropoietin, a hormone normally produced by healthy kidneys to stimulate production of red blood cells in the bone marrow. Lack of this substance due to kidney disease cannot be replaced, this despite many years of investigation seeking a way to do so. This anemia is markedly aggravated by the 45 need to sample the patient's blood frequently for chemical analysis of the blood plasma in order to monitor the effectiveness of treatment and to determine the need for any adjustments as might be necessary due to the patient's deviations from 50 dietary restrictions.

The present practice is to take whole blood samples directly from the patient at the outset, at or toward the conclusion and sometimes during the hemodialysis treatment. In the case of each 55 sample the plasma is thereafter separated from the blood (i.e. the cellular and other formed components, including the red blood cells), generally by centrifuging, and the plasma analyzed to determine its composition, or more 60 specifically, its waste product content.

This present procedure of taking multiple samples of the patient's whole blood has the aforesaid serious disadvantage of loss to the patient of a significant amount of red blood cells.

Whereas at least in connection with hemodialysis the conventional method used for separating the plasma from the cellular components of the blood is by centrifuging, it is known that blood plasma can be separated from the cellular components by filtration of the blood through a cross-flow type filter having a filter medium of a pore size which blocks the passage of the cells while allowing passage of the plasma. United States Patent 3,705,100 discloses such a 75 filtration method. The method of this Patent 3,705,100 has been used for obtaining blood plasma from donors and for plasmaphoresis wherein a patient's blood plasma is removed, treated, and then returned to the patient.

80 Brief Statement of the Invention

65

90

100

105

The object of the present invention is to provide a filter and method whereby periodic samples of a hemodialysis patient's blood plasma can be obtained without loss of blood cells and with minimum loss of blood plasma to the patient, and in such manner that the analysis results for each sample taken accurately reflect the actual composition of the patient's blood plasma at the time the sample is taken. This is accomplished by flowing the patient's blood, as it flows to or from the hemodialyzer, through a flow chamber having a filter medium as a wall thereof disposed generally parallel to the direction of flow of the blood through the chamber (i.e. a cross-flow type filter), the filter medium having a pore size which blocks the passage of the blood cellular components but allows the passage of the blood plasma. Hence the patient undergoes no loss of blood cells but only loss of some plasma.

On the side of the filter medium oppositely disposed from the flow chamber there is a plasma chamber of small volume, not exceeding about 2 milliliters, to collect the plasma passing through the filter medium. A sealable opening is provided in the plasma chamber for withdrawing plasma samples therefrom.

In the preferred manner of operation the plasma chamber is initially filled with saline solution. With the plasma chamber filled with the saline solution and the opening to the plasma chamber sealed, no plasma flows through the filter medium and hence none is removed from the blood flowing through the flow chamber. When a plasma sample is desired the saline 115 solution is withdrawn from the plasma chamber, through the sealable opening, whereupon plasma flows through the filter medium until the chamber is filled with plasma. Such plasma is then withdrawn through the sealable opening as a 120 sample for analysis, during which withdrawal additional plasma can and does flow into the plasma chamber. However, after withdrawal of the plasma sample, saline solution is forced into the plasma chamber through the sealable opening

thereby driving the plasma in the chamber back through the filter medium and into the blood then

flowing through the flow chamber. This procedure is repeated each time a plasma sample is desired. By the use of this procedure there is assurance that in no case will a plasma sample taken from the plasma chamber include any plasma taken from the blood during withdrawal of a previous sample. Because the plasma chamber is of small volume, preferably not greatly exceeding the volume of the plasma sample required for analysis, the volume of saline solution required to injected into and then subsequently withdrawn is not great and hence the time required for performing same and for withdrawal of each plasma sample is minimal.

Hence, the filter and method enable accurate periodic analysis of the patient's blood plasma with the patient suffering no loss of red blood cells and only small loss of plasma and with minimal time required for obtaining the needed plasma samples.

These and other features and advantages of the invention and its preferred embodiments will appear more clearly from the detailed description thereof which follows.

25 Brief Description of the Drawings

Figure 1 is a diagrammatic view of a dialyzer system incorporating the filter and for the practice of the method of the present invention;

Figure 2 is an exploded view, in enlarged scale, of 30 the filter shown as a component of the system of Figure 1;

Figure 3 is a side view in section, but in still larger scale, of the filter of the Figure 1 system;

Figure 4 is a top view of the filter shown in 35 Figure 3;

Figure 5 is a sectional view taken on the line -5 of Figure 3; and

Figure 6 is a sectional view taken on the line 6-6 of Figure 3.

40 Best Mode for Carrying Out the Invention

Referring to Figure 1, the hemodialysis system shown comprises a dialyzer 2, which can be of conventional construction, having a blood inlet opening 4, a blood outlet opening 6, and dialyzate inlet and outlet openings 8 and 10, there being a flexible tube which serves as a conduit 12 for conveying the blood from the patient 14 to the dialyzer blood injet 4, and another flexible tube which serves as the conduit 16 for conveying the blood from the dialyzer blood outlet back to the patient 14. The system includes suitable instrumentation and controls, well known in the and control panel 18, and a blood pump for

art, diagrammatically illustrated by the instrument causing flow of the patient's blood to and through the dialyzer and then back to the patient, such pump conventionally being of the roller type and diagrammatically illustrated at 20. A filter 22 embodying the present invention is included as a component of one or the other of the conduits conveying the patient's blood to or from the dialyzer, in the system shown, the filter being a component of the conduit conveying the blood

from the dialyzer to the patient. Other than the filter 22, the hemodialysis system and its operation for removing waste products from the patient's blood can be as well known in the art and hence requires no further description.

Referring now to Figures 2 through 6, the filter 22 comprises a housing having a blood flow chamber 24 with a blood inlet 26 and a blood outlet 28 connected to conduit 16, as shown, such that the blood flow chamber constitutes a part of the conduit, and a plasma chamber 30. The plasma chamber is separated from the blood flow chamber 24 by a filter medium 32, preferably a porous membrane, which extends parallel to the direction of flow of the blood

through the blood flow chamber. The filter 80 medium 32 is of a pore size which enables the passage of the blood plasma therethrough while blocking the passage of the red blood cells and other cellular components and platelets of the blood, the desired pore size being nominally about 85 .6 microns.

In the preferred embodiment shown the filter housing 23 comprises two molded plastic components, 34 and 36, preferably of a transparent thermoplastic, the upper component 34 providing the blood flow chamber and the lower component 36 providing the plasma chamber with opening 38 which is closed by a body 40 of a soft elastomer or like resilient material. The inlet and outlet openings, 26 and 28 95 respectively, for the blood flow chamber, are provided by tubular plastic moldings, 27 and 29 respectively, which are bonded and sealed into the openings at the axial ends of the upper plastic molding 34 and to which the ends of the flexible conduit 16 are secured, as shown, with a tight sealed fit provided by the inherent elasticity of the conduit. Each of the filter housing components 34 and 36 has a peripheral outwardly extending flange, 42 and 44 respectively, providing opposed surfaces which are bonded and sealed together with the periphery of the filter medium 32 bonded and sealed therebetween whereby the only communication between the blood flow chamber and the plasma chamber is through the filter 110 medium.

100

115

125

As shown and as thus far described, the filter will be recognized as being of a cross-flow type. That is, the blood flows through the flow chamber in a direction generally parallel to the surface of the filter medium, flow force components within the flow pattern and the pressure differential between the blood flow chamber and the plasma chamber (when the latter is not filled and sealed) causing the blood plasma to pass through the filter medium into the plasma chamber. To improve the efficiency the blood flow chamber should preferably be such as to provide a high filter medium surface-to-flow chamber volume ratio and to provide high velocity flow of the blood over the surface of the filter medium. To this end, in the preferred embodiment shown the center portion 45 of the blood flow chamber is flat (as is also the filter medium), and of small height, the

distance between the filter medium and the top wall of the chamber preferably not exceeding about 1.5 millimeter and ideally about 1 mm. Also, the center portion 45 of the blood flow

chamber is of a cross-sectional area (transverse to the direction of flow of the blood) preferably no less than, and most preferably about the same as, the cross-sectional area of the blood inlet and outlet openings 26 and 28 respectively, so that

10 the blood flow chamber does not serve to restrict the rate of flow of blood through the conduit, but with the blood flow velocity not being significantly less than the velocity in the conduit.

In conventional hemodialyzer systems the rate
of flow of the blood is from about 150 to 300
milliliters per minute and the blood flow rate, i.e.
velocity, even at the low end of this range (150
milliliters per minute) is sufficiently high to
provide excellent performance by the filter in the
flow of plasma through the membrane. In the
preferred embodiment shown, though in enlarged
scale, the actual dimensions of the center flat
portion 45 of the blood flow chamber are: length,
about 63.5 mm; width, about 21.8 mm; heighth,
about 1.02 mm. The nominal blood flow velocity
through the blood flow chamber is from about
150 to 300 milliliters per second.

As best seen in Figure 2, the plasma chamber 30 is of rectangular shape and, as best seen in Figures 2, 3 and 6, is very shallow and has a plurality of ribs 46 which function to support the filter medium and which have grooves 48 therebetween, all of which grooves communicate with the plasma chamber outlet opening 38 by way of a channel 48 at one end of the grooves and transverse thereto. Hence, the volume of the plasma chamber for reception of the plasma is the additive volume of the grooves and channel plus the volume of the outlet passage 49 between the channel and the inner surface of the elastomeric body 40 in the opening. In accordance with the invention this volume of the plasma chamber is very small, not exceeding about 2 milliliters and ideally being only about .5 milliliters.

The top surfaces of the ribs 46 in the plasma chamber define a flat surface against which the flat rectangular center portion of the filter medium rests, this planar surface defined by the top surfaces of the ribs being coplanar with the entire rectangular periphery of component 36 which surrounds the plasma chamber.

Referring again to the blood flow chamber 24, each of the end portions 50 and 52 is preferably shaped such that the cross-sectional area thereof and therealong (transverse to the direction of flow of the blood) is not less than, and preferably about the same as, the cross-sectional area of the center portion 45 of the blood flow chamber and, likewise, the cross-sectional area of the blood inlet and outlet openings 26 and 28 which are of about the same diameter as the internal diameter of the conduit 16. Again this is to assure that the blood flow chamber does not, at any point therealong, serve as a restriction on the flow of blood through the conduit and through the

system. As best seen in Figure 3, in the preferred embodiment shown, the height H of the end portion 50 gradually decreases from the opening 26 to the longitudinal end 54 of the rectangular center portion 45 of the blood flow chamber; but the width W (see Figure 4) of the end portion gradually increases from the opening 26 to the longitudinal end 54 of the center portion. The end portion 52 is of the same shape, tapered in height and reversely tapered in width, between opening 28 and the end 56 of the flow chamber center portion, thereby to provide the desired substantially uniform cross-section area transverse to the direction of blood flow. In addition to providing the uniform cross-sectional area, the shape of the end portions, as shown and described, serves to avoid or reduce the creation of turbulence in the flow of the blood as it enters, flows through and leaves the blood flow 85 chamber—this by providing a relatively gradual transition in the cross-sectional shape of the flow path between the flat center portion of the flow chamber and the cylindrical conduits. That is, as the blood enters the flow chamber through the cylindrical inlet 26 and as it leaves the flow chamber through the outlet 28, there is bound to be some turbulence but by shaping the portions 50 and 52 of the blood flow chamber as shown and described there is better assurance that the amount of turbulence is minimized. To further reduce the amount of turbulence in the blood flow as the blood enters, passes through and leaves the blood flow chamber it is preferred that the length of the tapered portion 50 (from the inlet 26 100 to the edge 54 of the rectangular portion) be at least three times, and most preferably about five times, the diameter of the cylindrical inlet 26; and likewise it is preferred that end portion 52 be of

diameter as the opening 26.

It will further be noted that in the preferred embodiment as shown, the rectangular center portion 50 of the blood flow chamber is elongated in the direction of flow of the blood, the length of the rectangular portion being more than twice its width. The elongated shape of the rectangular portion 50 is desirable in providing the desired thin flow chamber (i.e. small dimension from filter medium to the upper wall) and a high filter medium area-to-flow chamber volume ratio, along with the avoidance of turbulence.

such length relative to the outlet opening 28-

portion 50, the opening 28 being of the same

105 and hence of about the same length as end

The start-up and operation of the hemodialysis

120 system as a whole, aside from the filter 22, can be
as well known in the art for such systems. At
start-up, it is conventional to fill the entire blood
circulatory system, i.e. the conduits and dialyzer,
with a saline solution, thereby to exclude all air in

125 the system. Upon actuation of the pump 20 the
saline solution can be either partially or entirely
expelled prior to connection of conduit 16 to the
patient or the conduit 16 can be connected to the
patient prior to any or all of the saline solution

130 being expelled, any remaining saline solution in

35

the system being added as a component to the patient's blood, as may be varied from patient to patient depending on what is desirable as determined by the patient's physician. As regards the filter 22, since the blood flow chamber is a component of the conduit 16, the blood flow chamber will, following conventional procedure, be filled with saline solution at start-up of the system.

10 In the practice of the preferred method of the present invention, either prior to or after the filter 22 is connected to the conduit, but prior to circulation of the patient's blood through the conduit and system, the plasma chamber 30 is filled with saline solution. This can be simply and conveniently accomplished by piercing the elastomeric body with the hypodermic needle of a saline solution-filled syringe (not shown) and then injecting the saline solution into the plasma chamber through the needle by pressing the plunger of the syringe in the conventional manner. To best assure that no air is trapped in the plasma chamber during such injection of the saline solution, it is best that during the injection of the 25 saline solution the filter be oriented with the plasma chamber on the bottom and the blood flow chamber on the top as shown. The saline solution can and should be injected until it penetrates completely through the filter medium. After the plasma chamber is filled with the saline solution, with all air being excluded from the system, the patient's blood is caused to flow through the system in the conventional manner, by actuation of the blood pump.

Since it is desirable to obtain and then analyze the patient's blood plasma at the very outset of the hemodialysis treatment, immediately after the patient's blood has been caused to circulate through the system, the saline solution in the plasma chamber is withdrawn (during which withdrawal blood plasma flows through the filter medium into the plasma chamber to replace the saline solution), and then a plasma sample is withdrawn from the plasma chamber. All of this 45 can be conveniently accomplished by piercing the elastomeric body with the hypodermic needle of an empty syringe (not shown), withdrawing the saline solution from the plasma chamber by withdrawal of the syringe plunger in the 50 conventional manner; and then piercing the elastomeric body with the hypodermic needle of another empty syringe and withdrawing the plasma sample into such syringe. Variations in such procedure can, of course, be used. For example, the hypodermic needle of the syringe used to initially fill the plasma chamber with

whereupon the same syringe can be used to 60 withdraw the saline solution without ever removing the hypodermic needle from the elastomeric body. Further, instead of using an elastomeric body and one or more syringes, a valving arrangement can be used for the opening

saline solution can be left in place until the patient's blood is circulating through the system

65 38 of the plasma chamber with the valve or

valves connected by suitable conduits to small containers for injecting saline solution into the plasma chamber from one of the containers, withdrawing the saline solution from the plasma chamber into the same container, and withdrawing the plasma sample into the other container. But whatever the particular apparatus used, be it one or more syringes or otherwise, it should preferably be such as to cause some suction on the plasma chamber when the saline solution and when the plasma sample are withdrawn, thereby providing at least a somewhat greater pressure differential across the filter medium, during the withdrawal, than just the pressure differential resulting from the pressure of the blood in the blood flow chamber caused by the additive pressures of the patient's heart and the blood pump of the hemodialysis system. In conventional hemodialyzer systems the blood flow is at a pressure of about 150 to 250 milliliters Hg which is sufficient to cause the plasma to flow through the membrane into the plasma chamber, and any suction applied to the plasma chamber during withdrawal of the plasma therefrom is additive to this and hence somewhat increases the rate of flow of the plasma through the membrane while the suction is applied. With the aforesaid small volume of the plasma chamber, the aforesaid dimensions for the center portion 45 of the blood flow chamber and at the aforementioned blood flow rate, it requires only about one-half minute to one minute for sufficient plasma to flow through the membrane to fill the plasma chamber as and after the saline solution is

100 withdrawn. After each plasma sample is withdrawn, at which time the plasma chamber will be filled with additional plasma which has passed through the filter medium, the plasma chamber is refilled with saline solution by forcing saline solution into the chamber, as through a hypodermic needle pierced through the elastomeric body. As the saline solution is forced into the plasma chamber, the plasma therein is forced through the filter medium back into the blood flowing through the blood flow chamber, and to assure that all the plasma in the chamber is forced through the filter medium into the blood flow chamber it is desirable that the amount of saline solution injected be at least 115 somewhat in excess of the volume of the plasma chamber, resulting in some of the saline solution being forced through the filter medium into the blood flow chamber thereby to flush the filter medium of the plasma.

The entire procedure is repeated each time a 120 plasma sample is desired and it will be seen that in no case will a plasma sample taken include any plasma from a preceding sample taken. Hence, the analysis results for each plasma sample will 125 accurately reflect the composition of the patient's blood plasma at the time the sample is taken, and with minimum loss of plasma to the patient. Even more important, the plasma samples are obtained without loss of red blood cells to the patient.

130 The aforesaid method is preferred because it

provides optimum assurance that each plasma sample withdrawn does not contain any plasma the same as that of a previous sample. However, because the plasma chamber is of such small volume it is feasble to obtain the plasma sample or samples without the use of saline solution to fill the plasma chamber. That is, even without the use of the saline solution, the first plasma sample withdrawn from the plasma chamber at the 10 outset of the hemodialysis will contain only plasma of a composition the same as then in the patients blood. As for subsequent plasma samples withdrawn (without the intermediate filling of the plasma chamber with saline solution), prior to withdrawing each quantity of plasma desired for the sample, an initial quantity of plasma at least equal to the volume of the plasma chamber can be withdrawn and discarded, such discarded plasma being that which fills the chamber during and immediately after withdrawal of the previous plasma sample taken. During the withdrawal of the initial quantity of plasma, which is discarded, the plasma chamber refills with plasma from the blood then flowing through the blood flow chamber, it being this plasma which is withdrawn as the sample for analysis. Hence, each plasma sample withdrawn for analysis is of a composition substantially the same as that in the patient's blood at the time the sample is taken; however 30 there is greater loss of plasma to the patient as compared to the preferred method (wherein saline solution is used) by reason of the plasma which is discarded. However, as indicated above, this is no serious disadvantage because of the small volume of the plasma chamber whereby only a small volume of plasma need be discarded to avoid contaminating any sample by plasma the same as that of the preceding sample.

It will be understood that whereas in the
combodiment shown and described the filter is for
connection into the blood conduit intermediate
the ends thereof, the filter can, if desired, be
connected directly to the hemodialyzer, either to
its blood inlet or blood outlet, so as to form a
component thereof. This and other changes and
modifications can be made all within the full and
intended scope of the claims which follow.

CLAIMS

1. A filter having particular utility for obtaining 50 blood plasma samples from a patient's blood as the blood is being conveyed through a conduit during hemodialysis, said filter comprising a housing having a blood flow chamber and a plasma chamber separated from each other by a filter medium which extends generally parallel to the direction of flow of the blood through the blood flow chamber and which has a pore size allowing the passage therethrough of the plasma of the blood while blocking the passage therethrough of the red cells of the blood, said blood flow chamber having a blood inlet and a blood outlet for connection into the conduit whereby the blood being conveyed flows through the blood flow chamber, and said plasma

65 chamber having an opening for withdrawal of blood plasma therefrom and having a volume not exceeding about 2 milliliters.

2. A filter device as set forth in Claim 1 wherein said plasma chamber has a volume of about .5 milliliters.

3. A filter as set forth in Claim 1 wherein the blood flow chamber has a center portion of substantially uniform height, above the filter medium, not exceeding about 1.5 millimeter.

75

90

4. A filter as set forth in Claim 3 wherein the center portion of the blood flow chamber is of rectangular shape elongated in the direction of flow of the blood, wherein the blood inlet and the blood outlet are of circular cross-section, and wherein blood flow chamber has an end portion extending from one end of said elongated rectangular center portion to the blood inlet and an end portion extending from the other end of said elongated rectangular center portion to said blood outlet, each of said end portions having a substantially uniform cross-sectional area therealong at least approximately equal to the cross-sectional area of said center portion of the blood flow chamber.

5. The filter as set forth in Claim 1 wherein said plasma chamber has a wall oppositely disposed from said filter medium with elongated ribs which have upper surfaces in supporting contact with the filter medium and which have grooves therebetween which communicate with the opening of the plasma chamber.

6. A filter as set forth in Claim 1 wherein the opening of said plasma chamber comprises a body of puncturable, self-sealing, soft resilient material whereby plasma can be withdrawn from the opening through a hypodermic needle.

7. A method for obtaining a blood plasma sample from a patient's blood during hemodialysis comprising flowing the patient's blood during the hemodialysis through a blood flow chamber separated from a plasma chamber by a filter medium of a pore size which blocks the flow of the red cells of the blood therethrough while allowing the passage of the blood plasma therethrough into the plasma chamber, and withdrawing a blood plasma sample from the plasma chamber.

8. A method as set forth in Claim 7 wherein prior to withdrawing the blood plasma sample the plasma chamber is filled with saline solution, the saline solution thereafter being withdrawn from the plasma chamber before the plasma sample is withdrawn.

9. A method as set forth in Claim 8 wherein the
 120 plasma chamber is filled with saline solution prior to commencing flow of the patient's blood through the blood flow chamber.

10. A method as set forth in Claim 7 wherein after withdrawing the blood plasma sample from the plasma chamber, the blood plasma chamber is refilled with saline solution whereby blood plasma then in the chamber is forced by the incoming saline solution back through the filter medium and into the blood flow chamber.

11. A method as set forth in Claim 10 wherein the saline solution with which the plasma chamber is refilled is subsequently withdrawn from the plasma chamber whereby blood plasma
5 can again flow through the filter medium into the plasma chamber, another blood plasma sample then being withdrawn from the plasma chamber.

12. A method as set forth in Claim 7 wherein after the plasma sample is withdrawn and after 10 further passage of plasma through the filter

medium to fill the plasma chamber, a volume of plasma at least equal to the volume of the plasma chamber is withdrawn from the plasma chamber after which another plasma sample is withdrawn from the plasma chamber.

 A filter substantially as herein described and shown in the accompanying drawings.

14. A method substantially as herein described with reference to the accompanying drawings.

Printed in the United Kingdom for Her Majesty's Stationery Office, Demand No. 8818935, 9/1984. Contractor's Code No. 6378. Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.